Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht1f agonists

Abstract

The present invention relates to compounds of formula I: or a pharmaceutically acceptable acid addition salt thereof, wherein X is C(R3 c )═ or N═; R 1 is C 2 -C 6 alkyl, substituted C 2 -C 6 alkyl, C 3 -C 7 cycloalkyl, substituted C 3 -C 7 cycloalkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle; R 2 is hydrogen, C 1 -C 3 n-alkyl, C 3 -C 6 cycloalkyl-C 1 -C 3 alkyl, or a group of formula II provided that when R 1 is C 2 -C 6 alkyl or substituted C 2 -C 6 alkyl, R 2 is hydrogen or methyl; R 3a , R 3b and, when X is —C(R 3c )═, R 3c , are each independently hydrogen, fluoro, or methyl, provided that no more than one of R 3a , R 3b , and R 3c may be other than hydrogen; R 4 is hydrogen or C 1 -C 3 alkyl; R 5 is hydrogen, C 1 -C 3 alkyl, or C 3 -C 6 cycloalkylcarbonyl, provided that when R 3a is other than hydrogen, R 5 is hydrogen; R 6 is hydrogen or C 1 -C 6 alkyl; and n is an integer from 1 to 6 inclusively. The compounds of the present invention are useful for activating 5HT 1F receptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine in a mammal.

1 . A compound selected from 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         2 . The compound according to  claim 1  wherein the pharmaceutically acceptable salt is selected from mono-hydrochloride, di-hydrochloride, di-trifluoroacetate, and fumarate. 
     
     
         3 . A pharmaceutical composition comprising an effective amount of the compound or pharmaceutically acceptable salt according to  claim 1  and a pharmaceutical carrier, diluent, or excipient. 
     
     
         4 . A pharmaceutical composition comprising an effective amount of the pharmaceutically acceptable salt according to  claim 2  and a pharmaceutical carrier, diluent, or excipient. 
     
     
         5 . A method for the treatment or prevention of migraine in a mammal comprising administering to a mammal in need of such treatment or prevention an effective amount of a compound selected from 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
     
     
         6 . The method according to  claim 5  wherein the mammal is a human. 
     
     
         7 . A compound 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof.